Synthesis, spectral analysis and pharmacological study of N'- substituted-2-(5-((2,4-dimethylphenoxy)methyl)-1,3,4-oxadiazol-2-ylthio)acetohydrazides by Rasool, Shahid et al.
*Correspondence: A.-ur-Rehman. Department of Chemistry. Government 
College University. Lahore-54000, Pakistan. E-mail: azizryk@yahoo.com, 
rehman@gcu.edu.pk
A
rt
ic
leBrazilian Journal of 
Pharmaceutical Sciences
vol. 52, n. 3, jul./sep., 2016
http://dx.doi.org/10.1590/S1984-82502016000300013
Synthesis, spectral analysis and pharmacological study of 
N’‑substituted-2-(5-((2,4-dimethylphenoxy)methyl)-1,3,4-
oxadiazol-2-ylthio)acetohydrazides
Shahid Rasool1, Aziz-ur-Rehman1,*, Muhammad Athar Abbasi1, Sabahat Z Siddiqui1, 
Syed Adnan Ali Shah2,3
1Department of Chemistry, Government College University, Lahore, Pakistan; 2Faculty of Pharmacy, University Technology 
MARA, Puncak Alam Campus, 42300 Bandar Puncak Alam, Selangor Darul Ehsan, Malaysia; 3Atta-ur-Rahman Institute 
for Natural Products Discovery (AuRIns), Level 9, FF3, University Teknologi MARA, Puncak Alam Campus, 42300 Bandar 
Puncak Alam, Selangor Darul Ehsan, Malaysia
A series of molecules bearing multiple functional groups were synthesized to study their antibiotic effect 
against Gram-positive and Gram-negative bacteria and lipoxygenase activity as well. 2,4-Dimethylcarbolic 
acid (1) was refluxed with ethyl 2-bromoacetate to synthesize ethyl 2-(2,4-dimethylphenoxy)acetate (2). 
Compound 2 was converted to the corresponding hydrazide 3, again on refluxing with hydrazine. The 
compound 5-((2,4-dimethylphenoxy)methyl)-1,3,4-oxadiazol-2-thiol (4) was synthesized by the reaction 
of 3 and CS2 in the presence of KOH. Compound 4 was further converted to the corresponding ester 5 
and then 2-(5-((2,4-dimethylphenoxy)methyl)-1,3,4-oxadiazol-2-ylthio)acetohydrazide (6). The final 
molecules N’-substituted-2-(5-((2,4-dimethylphenoxy)methyl)-1,3,4-oxadiazol-2-ylthio)acetohydrazide, 
8a-m, bearing ether, 1,3,4-oxadiazole, thioether, hydrazone and azomethine functional groups were 
synthesized by stirring the aryl carboxaldehydes 7a-m with 6 in methanol at room temperature. The 
depicted structures of all synthesized molecules were corroborated by IR, 1H-NMR and EIMS spectral 
data analysis. 8m and 8i showed substantial antibacterial activity and lipoxygenase inhibitory activity, 
respectively.
Uniterms: Acetohydrazides/ Synthesis. Acetohydrazides/Antibacterial activity/ Acetohydrazides/
Lipoxygenase/inhibition activity.
INTRODUCTION
1,3,4-Oxadiazole heterocycle and azomethine 
derivatives are known to be involved in a variety of 
biological activities, and a few examples of them are 
described here. Regarding 1,3,4-oxadiazole heterocycle, 
antibacterial activity has been found for 2-aryl-7-alkyl/
aryl-[1,3,4]-oxadiazolo[3,2-a][1,3,5]triazin-5-one/
thione (Deshmukh et al., 2011), anticonvulsant activity 
for 2-(2-phenoxy)phenyl-1,3,4-oxadiazole derivatives 
(Tabatabai et al., 2013), antitumor activity for salicylic 
acid-based 1,3,4-oxadiazole derivatives (Murty et al., 
2014), and anticancer activity for 1-(1H-benzo[d]imidazol-
2-yl)-3-(1,3,4-oxadiazol-5-substituted derivatives-2-yl)
propan-1-ones (Rashid, Husain, Mishra, 2012). The 
1,3,4-oxadiazole moiety has also shown preferable 
binding to the active site of an enzyme through its 
oxygen (Zhang et al., 2011). With regard to azomethine 
derivatives, antibacterial and antifungal activities have 
been found for 2-(5-benzoyl-1H-benzo[d][1,2,3]triazol-
1-yl)-N’-arylidene acetohydrazide (Narsibhai et al., 
2012), antifungal activity (against Aspergillus niger and 
A. flavus), antioxidant activities for azomethine-N-oxides 
(Salman, 2013), and antibacterial along with antifungal 
and antiviral activities for azomethine derivatives of 
isoniazid bearing a 1,3,4-oxadiazole nucleus (Somani 
et al., 2011). Catalytic enantioselective 1,3-dipolar 
cycloadditions of azomethine ylides have been evaluated 
for biological activity (Narayan et al., 2014). Kamel et al. 
(2010) synthesized azomethine compounds and studied 
their interaction through molecular docking. The results 
proved them to possess higher binding energies with 1-3 
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hydrogen bonds. Thus, this functional group would allow 
considerable binding with the amino acid residues at the 
active site of an enzyme. All these findings were also 
supported by Aslam et al. (2011). 
All synthesized compounds were evaluated 
for antibacterial activity against certain strains of 
Gram-positive (Bacillus subtilis and Staphlyococcus 
aureus) and Gram-negative (Echerichia coli, S. typhi 
and Pseudomonas aeruginosa) bacteria. B. subtilis is 
believed to be harmless but produces subtilisin, which 
causes dermal allergic or hypersensitivity reactions 
with long exposure (Barbe et al., 2009), and S. aureus 
is pathogenic because it can adhere to the extracellular 
matrix and plasma proteins on biomaterials (Harris, Foster, 
Richards, 2002). E. coli is also thought to be harmless 
but causes food poisoning (Vogt, Dippold, 2005). The 
other strains, S. typhi and P. Aeruginosa, are associated 
with enteric fever (Bhattacharya, Das, Choudhury, 2011) 
and chronic infection (Pressler et al., 2011), respectively. 
The synthesized compounds were also tested for enzyme 
inhibitory activity against lipoxygenase. Lipoxygenases 
(EC 1.13.11.12) are widely distributed in animals and 
plants. They are involved in arachidonic acid metabolism 
and also generate various biologically active lipids that 
have a primary role in inflammation. Therefore, these are 
targets for drug development for the treatment of a variety 
of disorders such as bronchial asthma, inflammation etc. 
(Abbasi et al., 2005; Alitonou et al., 2006). 
Focusing on the future of these moieties in drug 
development owing to the notable biological activities 
and the results of previous work by our group (Aziz-ur-
Rehman et al., 2013a; Aziz-ur-Rehman et al., 2013b; Gul 
et al., 2013; Khalid et al., 2013), some new molecules of 
1,3,4-oxadiazole-bearing azomethine derivatives were 
synthesized and evaluated for their antibacterial and 
enzyme inhibition potential. A literature review has shown 
these moieties to have enzyme inhibitory and antibacterial 
activity. Thus, the synthesized molecules were tested for 
lipoxygenase inhibitory activity, in search of new anti-
inflammatory agents, and for antibacterial potential. 
MATERIAL AND METHODS
General
The chemicals were purchased through local 
suppliers from Alfa Aesar, Merck and Sigma-Aldrich. 
Analytical grade solvents were used without further 
purification. Thin layer chromatography (TLC) was the 
supporting tool for evaluation of purity of compounds 
and reaction completion, and carried out using silica gel 
G-25-UV254-coated aluminum plates and solvent systems 
of CH3COOC2H5 and n-C6H14 in varying proportions. The 
melting points of synthesized molecules were determined 
on a Griffin-George apparatus with an open capillary 
tube and were uncorrected. The spectral data included IR 
spectra using a Jasco-320-A spectrophotometer and KBr 
pellet method, 1H-NMR spectra obtained with a Bruker 
spectrometer in CDCl3 at 400 MHz, and EIMS spectra 
determined with a JMS-HX-110 spectrometer. 
Procedure for synthesis of ethyl 
2-(2,4-dimethylphenoxy)acetate (2)
2,4-Dimethylcarbolic acid (1; 0.05 mol) was added 
to 20 mL absolute ethanol in a 100-mL round bottom (RB) 
flask followed by solid KOH (0.05 mol). The reaction 
contents were refluxed for 0.5 hour. Ethyl 2-bromoacetate 
(0.05 mol) was then added and further refluxed for 6 
hours. The reaction was monitored by TLC. The reaction 
mixture was brought to room temperature and transferred 
to a 250-mL separatory funnel followed by 40 mL ice cold 
distilled water and 30 mL chloroform. The funnel was 
shaken vigorously and allowed to stand until there were 
two layers. The lower chloroform layer was separated 
and evaporated to afford 2. Light brown liquid; Yield: 
86%; Molecular formula: C12H16O3; Molecular weight: 
208 gmol-1; IR (KBr, vmax/cm-1): 3057 (Ar C-H), 1733 
(ester C=O), 1583 (Ar C=C), 1121 (C-O); 1H-NMR (400 
MHz, CDCl3, δ/ppm): 6.95 (s, 1H, H-3’), 6.85 (d, J = 8.0 
Hz, 1H, H-5’), 6.60 (d, J = 8.0 Hz, 1H, H-6’), 4.58 (s, 2H, 
H-2), 4.24 (q, J = 7.2 Hz, 2H, H-1’’), 2.23 (s, 3H, CH3-4’), 
2.20 (s, 3H, CH3-2’), 1.28 (t, J = 7.2 Hz, 3H, CH3-2’’); 
EIMS (m/z): 208 [M]+, 163 [C10H11O2]+, 135 [C9H11O]+, 
121 [C8H9O]+, 105 [C8H9]+, 93 [C7H9]+; Anal. Calcd for 
C12H16O3: C 69.21, H 7.74; found C 69.11, H 7.49.
Procedure for synthesis of 
2-(2,4-dimethylphenoxy)acetohydrazide (3)
The ester 2 (0.045 mol) and 80% hydrazine hydrate 
(0.045 mol) were added to 15 mL absolute ethanol in a 
100-mL RB flask and refluxed for 4 hours. After a final 
TLC check, the solvent was reduced to about 5 mL by 
distillation followed by the additiion of 30 mL cold 
distilled water. A precipitate appeared on gentle shaking 
and was acquired after filtration, washing and drying. Pink 
amorphous solid; Yield: 80%; Melting point: 164-166 oC; 
Molecular formula: C10H14N2O2; Molecular weight: 194 
gmol-1; IR (KBr, vmax/cm-1): 3412 (N-H), 3071 (Ar C-H), 
1667 (amide C=O), 1595 (Ar C=C), 1155 (C-O); 1H-NMR 
(400 MHz, CDCl3, δ/ppm): 6.96 (s, 1H, H-3’), 6.93 (d, J = 
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8.4 Hz, 1H, H-5’), 6.63 (d, J = 8.4 Hz, 1H, H-6’), 4.52 (s, 
2H, H-2), 2.24 (s, 3H, CH3-4’), 2.21 (s, 3H, CH3-2’); EIMS 
(m/z): 194 [M]+, 192 [C10H12N2O2]+, 163 [C10H11O2]+, 135 
[C9H11O]+, 121 [C8H9O]+, 105 [C8H9]+, 93 [C7H9]+; Anal. 
Calcd for C10H14N2O2: C 61.84, H 7.27, N 14.42; found C 
61.63, H 7.09, N 14.25.
Procedure for synthesis of 
5-((2,4-dimethylphenoxy)methyl)-1,3,4-oxadiazol-
2-thiol (4)
Compound 3 (0.04 mol) was mixed with 50 mL 
absolute ethanol in a 250-mL RB flask. Solid KOH (0.04 
mol) was added and the mixture refluxed until complete 
dissolution. The liquid CS2 (0.08 mol) was added strictly 
at RT. Again refluxing was continued for another 6 hours 
along with TLC guidance. The solvent was distilled off to 
one-third and added to excess cold distilled water. Dilute 
HCl (4-5 mL) was added to adjust to pH 5-6 and allowed to 
stand for 15 minutes. The precipitate was filtered, washed 
with distilled water and dried. Cream white amorphous 
solid; Yield: 86%; Melting point: 104-106 oC; Molecular 
formula: C11H12N2O2S; Molecular weight: 236 gmol-1; IR 
(KBr, vmax/cm-1): 3231 (Ar C-H), 2553 (S-H), 1673 (C=N), 
1587 (Ar C=C), 1092 (C-O); 1H-NMR (400 MHz, CDCl3, δ/
ppm): 6.95 (d, J = 8.4 Hz, 1H, H-5’), 6.92 (d, J = 1.6 Hz, 1H, 
H-3’), 6.75 (d, J = 8.4 Hz, 1H, H-6’), 4.99 (s, 2H, H-7’), 2.24 
(s, 3H, CH3-4’), 2.19 (s, 3H, CH3-2’); EIMS (m/z): 236 [M]+, 
203 [C11H11N2O2]+, 177 [C10H11NO2]+, 163 [C10H11O2]+, 161 
[C10H11NO]+, 135 [C9H11O]+, 121 [C8H9O]+, 105 [C8H9]+, 93 
[C7H9]+; Anal. Calcd for C11H12N2O2S: C 55.91, H 5.12, N 
11.86, S 13.57; found C 55.68, H 5.07, N 11.65, S 13.42.
Procedure for synthesis of ethyl 
2-(5-((2,4-dimethylphenoxy)methyl)-1,3,4-
oxadiazol-2-ylthio)acetate (5)
Compound 4 (0.035 mol) was dissolved in 15 mL 
dimethylformamide (DMF) in a 100-mL RB flask at RT 
followed by the addition of NaH (0.035 mol) and stirred 
for 30 minutes. Ethyl 2-bromoacetate (0.035 mol) was 
added and stirring continued for 4 hours. The reaction was 
checked by TLC. Excess cold distilled water was added 
with gentle shaking until precipitation. The precipitated 
product was filtered, washed with distilled water and dried. 
White amorphous solid; Yield: 81%; M.P.: 110-112 oC; 
Mol. formula: C15H18N2O4S; Mol. mass: 322 gmol-1; IR 
(KBr, vmax/cm-1): 3046 (Ar C-H), 1752 (Ester C=O), 1681 
(C=N), 1596 (Ar C=C), 1119 (C-O); 1H-NMR (400 MHz, 
CDCl3, δ/ppm): 6.94 (d, J = 8.0 Hz, 1H, H-5’), 6.90 (d, J 
= 1.2 Hz, 1H, H-3’), 6.72 (d, J = 8.0 Hz, 1H, H-6’), 4.97 
(s, 2H, H-7’), 3.93 (q, J = 7.2 Hz, 2H, -OCH2CH3), 4.67 
(s, 2H, H-2’’), 2.22 (s, 3H, CH3-4’), 2.18 (s, 3H, CH3-2’), 
1.02 (t, J = 7.2 Hz, 3H, -OCH2CH3); EIMS (m/z): 322 [M]+, 
203 [C11H11N2O2]+, 177 [C10H11NO2]+, 163 [C10H11O2]+, 161 
[C10H11NO]+, 135 [C9H11O]+, 121 [C8H9O]+, 105 [C8H9]+, 
93 [C7H9]+, 73 [C3H5O2]+; Anal. Calcd for C15H18N2O4S: 
C 55.88, H 5.63, N 8.69, S 9.95; found C 55.57, H 5.49, 
N 8.54, S 9.82.
Procedure for synthesis of 
2-(5-((2,4-dimethylphenoxy)methyl)-1,3,4-
oxadiazol-2-ylthio)acetohydrazide (6)
The ethyl ester 5 (0.03 mol) and 80% hydrazine 
hydrate (0.03 mol) were dissolved in 30 mL methanol 
in a 100-mL RB flask and stirred for 3 hours strictly at 
RT. TLC was used to monitor the reaction. The product 
was acquired after addition of excess cold distilled water 
and separated by filtration and washed and dried. Cream 
white amorphous solid; Yield: 83%; M.P.: 128-130 oC; 
Mol. formula: C13H16N4O3S; Mol. mass: 308 gmol-1; 
IR (KBr, vmax/cm-1): 3389 (N-H), 3071 (Ar C-H), 1673 
(Amide C=O), 1695 (C=N), 16041 (Ar C=C), 1115 (C-O); 
1H-NMR (400 MHz, CDCl3, δ/ppm): 9.41 (s, 1H, CONH), 
8.72 (s, 2H, N-H), 6.94 (d, J = 8.4 Hz, 1H, H-5’), 6.91 (d, J 
= 1.2 Hz, 1H, H-3’), 6.74 (d, J = 8.4 Hz, 1H, H-6’), 4.95 (s, 
2H, H-7’), 4.66 (s, 2H, H-2’’), 2.21 (s, 3H, CH3-4’), 2.19 
(s, 3H, CH3-2’); EIMS (m/z): 308 [M]+, 203 [C11H11N2O2]+, 
177 [C10H11NO2]+, 163 [C10H11O2]+, 161 [C10H11NO]+, 135 
[C9H11O]+, 121 [C8H9O]+, 105 [C8H9]+, 93 [C7H9]+; Anal. 
Calcd for C13H16N4O3S: C 50.64, H 5.23, N 18.17, S 10.40; 
found C 50.53, H 5.19, N 18.11, S 10.22.
General procedure for the synthesis of N’-
Substituted-2-(5-((2,4-dimethylphenoxy)methyl)-
1,3,4-oxadiazol-2-ylthio)acetohydrazide (8a-m)
The hydrazide 6 (0.004 mol) was dissolved in 
10 mL methanol in a 5- mL RB flask at RT. The aryl 
carboxaldehydes 7a-m (0.004 mol) were added and 
the mixture was stirred for 2 hours. The reaction was 
guided by TLC. Excess cold distilled water was added 
for precipitation. The precipitate formed was filtered, 
washed with distilled water and dried. All synthesized 
compounds were recrystallized from chloroform and 
tested for biological activity.
N’-Benzylidene-2-(5-((2,4-dimethylphenoxy)methyl)-
1,3,4-oxadiazol-2-ylthio)acetohydrazide (8a)
Light grey amorphous solid; Yield: 81%; M.P.: 
136-138 oC; Mol. formula: C20H20N4O3S; Mol. mass: 396 
S. Rasool, Aziz-ur-Rehman, M. A. Abbasi, S. Z Siddiqui, S. A. A. Shah474
gmol-1; IR (KBr, vmax/cm-1): 3057 (Ar C-H), 1659 (C=N), 
1614 (Ar C=C), 1093 (C-O); 1H-NMR (400 MHz, CDCl3, 
δ/ppm): 11.74 (s, 1H, CONH), 8.18 (s, 1H, H-7’’’), 7.74 
(dd, J = 7.6, 1.2 Hz, 2H, H-2’’’ & H-6’’’), 7.47-7.43 (m, 
3H, H-3’’’ to H-5’’’), 6.95 (d, J = 8.0 Hz, 1H, H-5’), 
6.92 (d, J = 1.6 Hz, 1H, H-3’), 6.71 (d, J = 8.4 Hz, 1H, 
H-6’), 4.91 (s, 2H, H-9’), 4.65 (s, 2H, H-2’’), 2.23 (s, 3H, 
CH3-8’), 2.19 (s, 3H, CH3-7’); EIMS (m/z): 396 [M]+, 
203 [C11H11N2O2]+, 177 [C10H11NO2]+, 163 [C10H11O2]+, 
161 [C10H11NO]+, 147 [C8H7N2O]+, 135 [C9H11O]+, 121 
[C8H9O]+, 119 [C7H7N2]+, 105 [C8H9]+, 105 [C7H5O]+, 93 
[C7H9]+, 91 [C7H7]+, 77 [C6H5]+, 65 [C5H5]+, 51 [C4H3]+; 
Anal. Calcd for C20H20N4O3S: C 60.59, H 5.08, N 14.13, 
S 8.09; found C 60.41, H 5.02, N 14.05, S 8.02.
N’-(2-Methylbenzylidene)-2-(5-((2,4-dimethylphenoxy)
methyl)-1,3,4-oxadiazol-2-ylthio)acetohydrazide (8b)
Dirty white amorphous solid; Yield: 81%; M.P.: 
148-150 oC; Mol. formula: C21H22N4O3S; Mol. mass: 410 
gmol-1; IR (KBr, vmax/cm-1): 3071 (Ar C-H), 1657 (C=N), 
1603 (Ar C=C), 1091 (C-O); 1H-NMR (400 MHz, CDCl3, 
δ/ppm): 11.71 (s, 1H, CONH), 8.36 (s, 1H, H-7’’’), 7.70 
(dd, J = 8.4, 1.2 Hz, 1H, H-6’’’), 7.37-7.33 (m, 2H, H-4’’’ 
& H-5’’’), 7.26 (d, J = 7.6 Hz, 1H, H-3’’’), 6.92 (d, J = 8.4 
Hz, 1H, H-5’), 6.92 (d, J = 1.2 Hz, 1H, H-3’), 6.73 (d, J = 
8.4 Hz, 1H, H-6’), 4.94 (s, 2H, H-9’), 4.66 (s, 2H, H-2’’), 
2.44 (s, 3H, CH3-8’’’), 2.23 (s, 3H, CH3-8’), 2.21 (s, 3H, 
CH3-7’); EIMS (m/z): 410 [M]+, 203 [C11H11N2O2]+, 177 
[C10H11NO2]+, 163 [C10H11O2]+, 161 [C10H11NO]+, 161 
[C9H9N2O]+, 135 [C9H11O]+, 133 [C8H9N2]+, 121 [C8H9O]+, 
119 [C7H5NO]+, 105 [C8H9]+, 93 [C7H9]+, 91 [C7H7]+; Anal. 
Calcd for C21H22N4O3S: C 61.44, H 5.40, N 13.65, S 7.81; 
found C 61.34, H 5.31, N 13.57, S 7.67.
N’-(3-Methylbenzylidene)-2-(5-((2,4-dimethylphenoxy)
methyl)-1,3,4-oxadiazol-2-ylthio)acetohydrazide (8c)
Light brown amorphous solid; Yield: 82%; M.P.: 
140-142 oC; Mol. formula: C21H22N4O3S; Mol. mass: 410 
gmol-1; IR (KBr, vmax/cm-1): 3053 (Ar C-H), 1682 (C=N), 
1614 (Ar C=C), 1083 (C-O); 1H-NMR (400 MHz, CDCl3, 
δ/ppm): 11.67 (s, 1H, CONH), 8.16 (s, 1H, H-7’’’), 7.41 
(d, J = 8.0 Hz, 1H, H-6’’’), 7.33 (t, J = 8.0 Hz, 1H, H-5’’’), 
7.27 (s, 1H, H-2’’’), 7.20 (d, J = 8.0 Hz, 1H, H-4’’’), 
6.93 (d, J = 8.4 Hz, 1H, H-5’), 6.93 (d, J = 1.2 Hz, 1H, 
H-3’), 6.72 (d, J = 8.4 Hz, 1H, H-6’), 4.93 (s, 2H, H-9’), 
4.67 (s, 2H, H-2’’), 2.32 (s, 3H, CH3-8’’’), 2.23 (s, 3H, 
CH3-8’), 2.21 (s, 3H, CH3-7’); EIMS (m/z): 410 [M]+, 
203 [C11H11N2O2]+, 177 [C10H11NO2]+, 163 [C10H11O2]+, 
161 [C10H11NO]+, 161 [C9H9N2O]+, 135 [C9H11O]+, 133 
[C8H9N2]+, 121 [C8H9O]+, 119 [C7H5NO]+, 105 [C8H9]+, 
93 [C7H9]+, 91 [C7H7]+; Anal. Calcd for C21H22N4O3S: C 
61.44, H 5.40, N 13.65, S 7.81; found C 61.34, H 5.31, N 
13.57, S 7.67.
N’-(4-Methylbenzylidene)-2-(5-((2,4-dimethylphenoxy)
methyl)-1,3,4-oxadiazol-2-ylthio)acetohydrazide (8d)
Light green amorphous solid; Yield: 84%; M.P.: 152-
154 oC; Mol. formula: C21H22N4O3S; Mol. mass: 410 gmol-1; 
IR (KBr, vmax/cm-1): 3047 (Ar C-H), 1656 (C=N), 1608 (Ar 
C=C), 1080 (C-O); 1H-NMR (400 MHz, CDCl3, δ/ppm): 
11.71 (s, 1H, CONH), 8.15 (s, 1H, H-7’’’), 7.61 (d, J = 8.4 
Hz, 2H, H-2’’’ & H-6’’’), 7.26 (d, J = 8.4 Hz, 2H, H-3’’’ 
& H-5’’’), 6.91 (d, J = 8.0 Hz, 1H, H-5’), 6.88 (d, J = 1.6 
Hz, 1H, H-3’), 6.72 (d, J = 8.0 Hz, 1H, H-6’), 4.93 (s, 2H, 
H-9’), 4.64 (s, 2H, H-2’’), 2.34 (s, 3H, CH3-8’’’), 2.23 (s, 
3H, CH3-8’), 2.20 (s, 3H, CH3-7’); EIMS (m/z): 410 [M]+, 
203 [C11H11N2O2]+, 177 [C10H11NO2]+, 163 [C10H11O2]+, 
161 [C10H11NO]+, 161 [C9H9N2O]+, 135 [C9H11O]+, 133 
[C8H9N2]+, 121 [C8H9O]+, 119 [C7H5NO]+, 105 [C8H9]+, 
93 [C7H9]+, 91 [C7H7]+; Anal. Calcd for C21H22N4O3S: C 
61.44, H 5.40, N 13.65, S 7.81; found C 61.34, H 5.31, N 
13.57, S 7.67.
N’-(2-Hydroxybenzylidene)-2-(5-((2,4-
dimethylphenoxy)methyl)-1,3,4-oxadiazol-2-ylthio)
acetohydrazide (8e)
Light yellow amorphous solid; Yield: 88%; M.P.: 
158-160 oC; Mol. formula: C20H20N4O4S; Mol. mass: 412 
gmol-1; IR (KBr, vmax/cm-1): 3069 (Ar C-H), 1677 (C=N), 
1607 (Ar C=C), 1092 (C-O); 1H-NMR (400 MHz, CDCl3, 
δ/ppm): 11.73 (s, 1H, CONH), 8.26 (s, 1H, H-7’’’), 7.72 
(dd, J = 8.0, 1.6 Hz, 1H, H-6’’’), 7.54 (dd, J = 8.4, 1.2 Hz, 
1H, H-3’’’), 7.23 (dt, J = 8.4, 1.6 Hz, 1H, H-4’’’), 6.90 
(d, J = 8.4 Hz, 1H, H-5’), 6.86 (d, J = 1.6 Hz, 1H, H-3’), 
6.84 (t, J = 8.0 Hz, 1H, H-5’’’), 6.74 (d, J = 8.4 Hz, 1H, 
H-6’), 4.93 (s, 2H, H-9’), 4.65 (s, 2H, H-2’’), 2.21 (s, 3H, 
CH3-8’), 2.19 (s, 3H, CH3-7’); EIMS (m/z): 412 [M]+, 
203 [C11H11N2O2]+, 177 [C10H11NO2]+, 163 [C10H11O2]+, 
163 [C8H7N2O2]+, 161 [C10H11NO]+, 135 [C9H11O]+, 135 
[C7H7N2O]+, 121 [C8H9O]+, 107 [C7H7O]+, 105 [C8H9]+, 93 
[C7H9]+; Anal. Calcd for C20H20N4O4S: C 58.24, H 4.89, 
N 13.58, S 7.77; found C 58.11, H 4.73, N 13.41, S 7.59.
N’-(3-Hydroxybenzylidene)-2-(5-((2,4-
dimethylphenoxy)methyl)-1,3,4-oxadiazol-2-ylthio)
acetohydrazide (8f) 
Light brown amorphous solid; Yield: 79%; M.P.: 
150-152 oC; Mol. formula: C20H20N4O4S; Mol. mass: 412 
gmol-1; IR (KBr, vmax/cm-1): 3043 (Ar C-H), 1675 (C=N), 
1609 (Ar C=C), 1079 (C-O); 1H-NMR (400 MHz, CDCl3, 
δ/ppm): 11.79 (s, 1H, CONH), 8.14 (s, 1H, H-7’’’), 7.21 
(t, J = 8.8 Hz, 1H, H-5’’’), 7.16 (s, 1H, H-2’’’), 7.09 (d, 
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J = 8.8 Hz, 1H, H-6’’’), 6.94 (d, J = 8.4 Hz, 1H, H-5’), 
6.90 (d, J = 1.6 Hz, 1H, H-3’), 6.85 (dd, J = 8.4, 2.0 Hz, 
1H, H-4’’’), 6.73 (d, J = 8.4 Hz, 1H, H-6’), 4.93 (s, 2H, 
H-9’), 4.64 (s, 2H, H-2’’), 2.20 (s, 3H, CH3-8’), 2.17 (s, 
3H, CH3-7’); EIMS (m/z): 412 [M]+, 203 [C11H11N2O2]+, 
177 [C10H11NO2]+, 163 [C10H11O2]+, 163 [C8H7N2O2]+, 
161 [C10H11NO]+, 135 [C9H11O]+, 135 [C7H7N2O]+, 121 
[C8H9O]+, 107 [C7H7O]+, 105 [C8H9]+, 93 [C7H9]+; Anal. 
Calcd for C20H20N4O4S: C 58.24, H 4.89, N 13.58, S 7.77; 
found C 58.11, H 4.73, N 13.41, S 7.59.
N’-(4-Hydroxybenzylidene)-2-(5-((2,4-
dimethylphenoxy)methyl)-1,3,4-oxadiazol-2-ylthio)
acetohydrazide (8g)
Brown crystalline solid; Yield: 81%; M.P.: 166-168 
oC; Mol. formula: C20H20N4O4S; Mol. mass: 412 gmol-1; 
IR (KBr, vmax/cm-1): 3037 (Ar C-H), 1671 (C=N), 1603 (Ar 
C=C), 1095 (C-O); 1H-NMR (400 MHz, CDCl3, δ/ppm): 
11.75 (s, 1H, CONH), 8.13 (s, 1H, H-7’’’), 7.51 (d, J = 8.4 
Hz, 2H, H-2’’’ & H-6’’’), 6.92 (d, J = 8.0 Hz, 1H, H-5’), 
6.89 (d, J = 1.6 Hz, 1H, H-3’), 6.81 (d, J = 8.8 Hz, 2H, 
H-3’’’ & H-5’’’), 6.74 (d, J = 8.0 Hz, 1H, H-6’), 4.94 (s, 
2H, H-9’), 4.65 (s, 2H, H-2’’), 2.24 (s, 3H, CH3-8’), 2.21 
(s, 3H, CH3-7’); EIMS (m/z): 412 [M]+, 203 [C11H11N2O2]+, 
177 [C10H11NO2]+, 163 [C10H11O2]+, 163 [C8H7N2O2]+, 
161 [C10H11NO]+, 135 [C9H11O]+, 135 [C7H7N2O]+, 121 
[C8H9O]+, 107 [C7H7O]+, 105 [C8H9]+, 93 [C7H9]+; Anal. 
Calcd for C20H20N4O4S: C 58.24, H 4.89, N 13.58, S 7.77; 
found C 58.11, H 4.73, N 13.41, S 7.59.
N’-(2-Nitrobenzylidene)-2-(5-((2,4-dimethylphenoxy)
methyl)-1,3,4-oxadiazol-2-ylthio)acetohydrazide (8h)
Yellow amorphous solid; Yield: 79%; M.P.: 146-148 
oC; Mol. formula: C20H19N5O5S; Mol. mass: 441 gmol-1; 
IR (KBr, vmax/cm-1): 3089 (Ar C-H), 1677 (C=N), 1613 (Ar 
C=C), 1115 (C-O); 1H-NMR (400 MHz, CDCl3, δ/ppm): 
12.01 (s, 1H, CONH), 8.35 (s, 1H, H-7’’’), 8.31 (d, J = 
8.4 Hz, 1H, H-6’’’), 7.95 (dd, J = 8.4, 1.6 Hz, 1H, H-3’’’), 
7.95-7.93 (m, 2H, H-4’’’ & H-5’’’), 6.91 (d, J = 8.8 Hz, 1H, 
H-5’), 6.88 (d, J = 2.0 Hz, 1H, H-3’), 6.76 (d, J = 8.8 Hz, 
1H, H-6’), 4.93 (s, 2H, H-9’), 4.65 (s, 2H, H-2’’), 2.23 (s, 
3H, CH3-8’), 2.21 (s, 3H, CH3-7’); EIMS (m/z): 441 [M]+, 
203 [C11H11N2O2]+, 192 [C8H6N3O3]+, 177 [C10H11NO2]+, 
164 [C7H6N3O2]+, 163 [C10H11O2]+, 161 [C10H11NO]+, 136 
[C7H6NO2]+, 135 [C9H11O]+, 121 [C8H9O]+, 105 [C8H9]+, 
93 [C7H9]+; Anal. Calcd for C20H19N5O5S: C 54.41, H 4.34, 
N 15.86, S 7.26; found C 54.27, H 4.22, N 15.68, S 7.19.
N’-(3-Nitrobenzylidene)-2-(5-((2,4-dimethylphenoxy)
methyl)-1,3,4-oxadiazol-2-ylthio)acetohydrazide (8i)
Light brown amorphous solid; Yield: 87%; M.P.: 
142-144 oC; Mol. formula: C20H19N5O5S; Mol. mass: 441 
gmol-1; IR (KBr, vmax/cm-1): 3086 (Ar C-H), 1652 (C=N), 
1606 (Ar C=C), 1093 (C-O); 1H-NMR (400 MHz, CDCl3, 
δ/ppm): 12.02 (s, 1H, CONH), 8.44 (t, J = 1.6 Hz, 1H, 
H-2’’’), 8.38 (s, 1H, H-7’’’), 8.21 (dd, J = 8.4, 1.6 Hz, 1H, 
H-6’’’), 8.12 (d, J = 8.8 Hz, 1H, H-4’’’), 7.69 (t, J = 8.4 
Hz, 1H, H-5’’’), 6.93 (d, J = 8.4 Hz, 1H, H-5’), 6.91 (d, J = 
1.2 Hz, 1H, H-3’), 6.71 (d, J = 8.4 Hz, 1H, H-6’), 4.92 (s, 
2H, H-9’), 4.65 (s, 2H, H-2’’), 2.24 (s, 3H, CH3-8’), 2.22 
(s, 3H, CH3-7’); EIMS (m/z): 441 [M]+, 203 [C11H11N2O2]+, 
192 [C8H6N3O3]+, 177 [C10H11NO2]+, 164 [C7H6N3O2]+, 
163 [C10H11O2]+, 161 [C10H11NO]+, 136 [C7H6NO2]+, 135 
[C9H11O]+, 121 [C8H9O]+, 105 [C8H9]+, 93 [C7H9]+; Anal. 
Calcd for C20H19N5O5S: C 54.41, H 4.34, N 15.86, S 7.26; 
found C 54.27, H 4.22, N 15.68, S 7.19.
N’-(4-Nitrobenzylidene)-2-(5-((2,4-dimethylphenoxy)
methyl)-1,3,4-oxadiazol-2-ylthio)acetohydrazide (8j) 
Brown amorphous solid; Yield: 79%; M.P.: 154-156 
oC; Mol. formula: C20H19N5O5S; Mol. mass: 441 gmol-1; 
IR (KBr, vmax/cm-1): 3087 (Ar C-H), 1665 (C=N), 1614 (Ar 
C=C), 1083 (C-O); 1H-NMR (400 MHz, CDCl3, δ/ppm): 
12.03 (s, 1H, CONH), 8.43 (s, 1H, H-7’’’), 8.13 (d, J = 8.0 
Hz, 2H, H-3’’’ & H-5’’’), 8.05 (d, J = 8.0 Hz, 2H, H-2’’’ 
& H-6’’’), 6.96 (d, J = 8.0 Hz, 1H, H-5’), 6.93 (d, J = 1.6 
Hz, 1H, H-3’), 6.72 (d, J = 8.4 Hz, 1H, H-6’), 4.93 (s, 2H, 
H-9’), 4.62 (s, 2H, H-2’’), 2.23 (s, 3H, CH3-8’), 2.21 (s, 
3H, CH3-7’); EIMS (m/z): 441 [M]+, 203 [C11H11N2O2]+, 
192 [C8H6N3O3]+, 177 [C10H11NO2]+, 164 [C7H6N3O2]+, 
163 [C10H11O2]+, 161 [C10H11NO]+, 136 [C7H6NO2]+, 135 
[C9H11O]+, 121 [C8H9O]+, 105 [C8H9]+, 93 [C7H9]+; Anal. 
Calcd for C20H19N5O5S: C 54.41, H 4.34, N 15.86, S 7.26; 
found C 54.27, H 4.22, N 15.68, S 7.19.
N’-(4-(Dimethylamino)benzylidene)-2-(5-((2,4-
dimethylphenoxy)methyl)-1,3,4-oxadiazol-2-ylthio)
acetohydrazide (8k)
Brown crystalline solid; Yield: 77%; M.P.: 178-180 
oC; Mol. formula: C22H25N5O3S; Mol. mass: 439 gmol-1; 
IR (KBr, vmax/cm-1): 3061 (Ar C-H), 1654 (C=N), 1614 (Ar 
C=C), 1111 (C-O); 1H-NMR (400 MHz, CDCl3, δ/ppm): 
11.47 (s, 1H, CONH), 8.04 (s, 1H, H-7’’’), 7.47 (d, J = 8.4 
Hz, 2H, H-2’’’ & H-6’’’), 6.97 (d, J = 8.4 Hz, 1H, H-5’), 
6.92 (d, J = 1.6 Hz, 1H, H-3’), 6.77 (d, J = 8.4 Hz, 1H, 
H-6’), 6.61 (d, J = 8.8 Hz, 2H, H-3’’’ & H-5’’’), 4.94 (s, 
2H, H-9’), 4.56 (s, 2H, H-2’’), 2.94 (s, 6H, CH3-8’’’ & CH3-
9’’’), 2.20 (s, 3H, CH3-8’), 2.17 (s, 3H, CH3-7’); EIMS 
(m/z): 439 [M]+, 203 [C11H11N2O2]+, 190 [C10H12N3O]+, 
177 [C10H11NO2]+, 163 [C10H11O2]+, 162 [C9H12N3]+, 161 
[C10H11NO]+, 135 [C9H11O]+, 134 [C9H12N]+, 121 [C8H9O]+, 
105 [C8H9]+, 93 [C7H9]+; Anal. Calcd for C22H25N5O3S: C 
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60.12, H 5.73, N 15.93, S 7.30; found C 60.07, H 5.66, N 
15.84, S 7.16.
N’-(4-(Diethylamino)benzylidene)-2-(5-((2,4-
dimethylphenoxy)methyl)-1,3,4-oxadiazol-2-ylthio)
acetohydrazide (8l)
Light brown amorphous solid; Yield: 78%; M.P.: 
186-188 oC; Mol. formula: C24H29N5O3S; Mol. mass: 467 
gmol-1; IR (KBr, vmax/cm-1): 3063 (Ar C-H), 1642 (C=N), 
1614 (Ar C=C), 1081 (C-O); 1H-NMR (400 MHz, CDCl3, 
δ/ppm): 11.43 (s, 1H, CONH), 8.04 (s, 1H, H-7’’’), 7.41 
(d, J = 8.4 Hz, 2H, H-2’’’ & H-6’’’), 6.93 (d, J = 8.0 
Hz, 1H, H-5’), 6.91 (d, J = 2.0 Hz, 1H, H-3’), 6.75 (d, 
J = 8.0 Hz, 1H, H-6’), 6.63 (d, J = 8.4 Hz, 2H, H-3’’’ & 
H-5’’’), 4.91 (s, 2H, H-9’), 4.61 (s, 2H, H-2’’), 2.63 (q, 
J = 7.6 Hz, 4H, H-8’’’ & H-10’’’), 2.19 (s, 3H, CH3-8’), 
2.17 (s, 3H, CH3-7’), 1.05 (t, J = 7.6 Hz, 6H, CH3-9’’’ & 
CH3-11’’’); EIMS (m/z): 467 [M]+, 218 [C12H16N3O]+, 
203 [C11H11N2O2]+, 190 [C11H16N3]+, 177 [C10H11NO2]+, 
163 [C10H11O2]+, 162 [C11H16N]+, 161 [C10H11NO]+, 135 
[C9H11O]+, 121 [C8H9O]+, 105 [C8H9]+, 93 [C7H9]+; Anal. 
Calcd for C24H29N5O3S: C 61.65, H 6.25, N 14.98, S 6.86; 
found C 61.52, H 6.12, N 14.84, S 6.71.
N’-(4-Methoxybenzylidene)-2-(5-((2,4-
dimethylphenoxy)methyl)-1,3,4-oxadiazol-2-ylthio)
acetohydrazide (8m)
Light green amorphous solid; Yield: 79%; M.P.: 
164-166 oC; Mol. formula: C21H22N4O4S; Mol. mass: 426 
gmol-1; IR (KBr, vmax/cm-1): 3066 (Ar C-H), 1646 (C=N), 
1610 (Ar C=C), 1084 (C-O); 1H-NMR (400 MHz, CDCl3, 
δ/ppm): 11.41 (s, 1H, CONH), 8.15 (s, 1H, H-7’’’), 7.82 (d, 
J = 8.4 Hz, 2H, H-2’’’ & H-6’’’), 6.94 (d, J = 8.4 Hz, 1H, 
H-5’), 6.91 (d, J = 1.6 Hz, 1H, H-3’), 6.74 (d, J = 8.4 Hz, 1H, 
H-6’), 6.55 (d, J = 8.4 Hz, 2H, H-3’’’ & H-5’’’), 4.92 (s, 2H, 
H-9’), 4.63 (s, 2H, H-2’’), 3.83 (s, 3H, CH3O-8’’’), 2.23 (s, 
3H, CH3-8’), 2.20 (s, 3H, CH3-7’); EIMS (m/z): 426 [M]+, 
203 [C11H11N2O2]+, 177 [C10H11NO2]+, 177 [C9H9N2O2]+, 
163 [C10H11O2]+, 161 [C10H11NO]+, 149 [C8H9N2O]+, 135 
[C9H11O]+, 121 [C8H9O]+, 107 [C7H7O]+, 105 [C8H9]+, 93 
[C7H9]+; Anal. Calcd for C21H22N4O4S: C 59.14, H 5.20, N 
13.14, S 7.52; found C 59.03, H 5.11, N 13.01, S 7.41.
BIOLOGICAL ACTIVITY ASSAYS
Antibacterial activity assay
Antibacterial activity was assayed as reported 
elsewhere, with minor modifications (Aziz-ur-Rehman 
et al., 2013c; Kaspady et al., 2009; Yang et al., 2006). 
The assay was performed in sterile 96-well microplates 
under aseptic conditions. The method is based on the 
principle that microbial cell number increases during log 
phase growth, resulting in increased absorbance of broth 
medium. The microorganisms used in this study included 
three Gram-negative bacteria, namely Salmonella typhi, 
Escherichia coli and Pseudomonas aeruginosa, and two 
Gram-positive bacteria, namely Bacillus subtilis and 
Staphylococcus aureus. The strains used were grown on 
stock agar culture medium. The test samples were diluted 
in suitable solvents and 20 µL of each sample was pipetted 
into every well. Fresh bacterial culture grown overnight 
was suitably diluted with fresh nutrient broth and 180 µL 
of this bacterial culture were added to every well. The 
starting absorbance of the culture at 540 nm was strictly 
maintained at 0.12-0.19. The total volume in each well 
was 200 µL. These microplates were incubated for 16-24 
hours at 37°C. Before and after incubation, the absorbance 
was measured at 540 nm using a microplate reader. 
Bacterial growth rate was determined by the difference in 
absorbance before and after incubation. The formula for 
calculating the percentage inhibition was: 
where X = absorbance in control, containing bacterial 
culture without test sample; Y = absorbance of bacterial 
culture with test sample. 
Results are given as the mean of three sets of test 
samples (n = 3, ± SEM). The reference standard used 
was ciprofloxacin. Suitable dilutions ranging from 5-30 
µg/well were used to measure the minimum inhibitory 
concentration (MIC).
Enzyme inhibition activity assay
Lipoxygenase enzyme inhibition activity was 
determined by a previously reported method, with minor 
modifications (Abbasi et al., 2005; Alitonou et al., 2006). 
A 200-µL reaction mix consisted of 150 µL 100 mM 
sodium phosphate buffer (pH 8.0), 10 µL test compound 
and 15 µL purified lipoxygenase enzyme (600 units well-1). 
After mixing, pre-reading at 234 nm and pre-incubation 
for 10 min at 25 °C (room temperature), 25 µL substrate 
solution were added to initiate the reaction. The results 
were based on the change in absorbance, observed after 
6 min at 234 nm using a microplate reader (Synergy HT, 
Biotek, USA). Assays were done in triplicate, and positive 
and negative controls were included in the assay. Baicalein 
(0.5 mM) was used as a positive control. The results were 
calculated according to the following formula.
Synthesis, spectral analysis and pharmacological study of N’-substituted-2-(5-((2,4-dimethylphenoxy)methyl)-1,3,4-oxadiazol-2-ylthio)acetohydrazides 477
where Control is the absorbance in the presence of 
reference and Test is the absorbance in the presence of 
the test compound. 
Statistical analysis 
The results are presented as mean ± SEM for 
triplicate calculations after statistical analysis executed 
by MS Excel 2010. Minimum inhibitory concentration 
(MIC) for antibacterial activity and IC50 (concentration 
with 50% inhibition) for enzyme inhibition was computed 
with suitable dilutions of each sample, and the results were 
obtained using EZ-Fit software (Perrella Scientific Inc, 
Amherst, USA).
RESULTS AND DISCUSSION
The N-substituted derivatives 8a-m were synthesized 
by the protocol given in Figure 1 and substituents in Table 
I. The multiple functional groups were synthesized to 
evaluate the combined effect of these moities against some 
strains of Gram-nagative and Gram-positive bacteria and 
against lipoxygenase activity.
Chemistry
The synthesis of ethyl 2-(2,4-dimethylphenoxy)
acetate (2) was carried out with reflux in the presence 
of a strong base. The harsh conditions were applied 
because of low acidity of 2,4-dimethylcarbolic acid 
(1) owing to two electron-donating methyl groups. 
2-(2,4-dimethylphenoxy)acetohydrazide (3) was also 
synthesized with reflux, because of the low electrophilic 
character of carbonyl carbon; otherwise, most of such 
reactions were performed with stirring. After synthesis of 
5-((2,4-dimethylphenoxy)methyl)-1,3,4-oxadiazol-2-thiol 
(4) with reflux in basic medium, it was filtered out from 
slightly acidic medium (pH 5-6). Such low pH is necessary 
to get maximum yield. The yield is much lower on 
filtration in basic medium or strong acidic medium because 
of salt formation. Molecule 4 possessed a more acidic 
proton as a thiol, so ethyl 2-(5-((2,4-dimethylphenoxy)
methyl)-1,3,4-oxadiazol-2-ylthio)acetate (5) was prepared 
simply by stirring in the presence of a weak base. 
2-(5-((2,4-Dimethylphenoxy)methyl)-1,3,4-oxadiazol-2-
ylthio)acetohydrazide (6) was also obtained with stirring 
at RT. The target molecules 8a-m were synthesized by 
stirring compound 6 with the aryl carboxaldehydes 7a-m 
in methanol. Although this step has reasonable speed, it 
can be catalyzed by a few drops of glacial acetic acid. All 
the protocols with necessary conditions are explained in 
the experimental section. 
Compound 8a was a light grey amorphous solid 
with a melting point of 136-138oC. Its molecular 
formula, C20H20N4O3S, was established with the aid of 
1H-NMR and EIMS spectra. The prominent peaks in the 
FIGURE 1 - Synthesis of N’-substituted-2-(5-((2,4-dimethylphenoxy)methyl)-1,3,4-oxadiazol-2-ylthio)acetohydrazide (8a-m). 
Results and Conditions: (I) Ethyl 2-bromoacetate (EBA), KOH, EtOH, Reflux, 6 hours (II) 80% N2H4.H2O, EtOH, Reflux, 4 
hours (III) CS2, KOH, EtOH, Reflux, 6 hours (IV) EBA, NaH, DMF, Stir, 4 hours (V) 80% N2H4.H2O, MeOH, Stir, 3 hours (VI) 
Aryl carboxaldehydes (7a-m), MeOH, Stir, 2 hours. 
S. Rasool, Aziz-ur-Rehman, M. A. Abbasi, S. Z Siddiqui, S. A. A. Shah478
EIMS spectrum were at m/z 396 (molecular ion), 203 
(5-((2,4-dimethylphenoxy)methyl)-1,3,4-oxadiazol-2-
thio cation) and 147 (N’-benzylidenehydrazinocarbonyl 
cation). The mass fragmentation pattern of 8a is elaborated 
in Figure 2. The major absorptions in the IR spectrum 
appeared at (cm-1) 3057 (Ar C-H), 1659 (C=N), 1614 (Ar 
C=C) and 1093 (C-O). The three aromatic protons of the 
phenoxy group showed three doublets, two with ortho 
coupling and one with meta coupling, resonating at δ 6.95 
(d, J = 8.0 Hz, 1H, H-5’), 6.92 (d, J = 1.6 Hz, 1H, H-3’) 
and 6.71 (d, J = 8.4 Hz, 1H, H-6’). The six protons of two 
methyl groups resonated at δ 2.23 (s, 3H, CH3-4’) and 
2.19 (s, 3H, CH3-2’). The five aromatic and one methine 
protons of the benzylidene moiety were confirmed by one 
singlet, one double doublet and one multiplet at δ 8.18 
(s, 1H, H-7’’’), 7.74 (dd, J = 7.6, 1.2 Hz, 2H, H-2’’’ & 
H-6’’’) and 7.47-7.43 (m, 3H, H-3’’’ to H-5’’’). The other 
three resonating peaks at δ 11.74 (s, 1H, CONH), 4.91 (s, 
2H, H-7’) and 4.65 (s, 2H, H-2’’) were allocated to one 
carbamoyl proton and two methylene groups. The above 
structural demonstration justified 8a as N’-benzylidene-
2-(5-((2,4-dimethylphenoxy)methyl)-1,3,4-oxadiazol-
2-ylthio)acetohydrazide. The other compounds were 
likewise corroborated. 
Biological activities
Subtle structural changes in molecules are known 
to have a great influence on the pharmacological behavior 
(Liu et al., 2012). Therefore, a series of compounds were 
synthesized that varied in nature and position of the 
substitutent present on the phenyl ring attached to the 
methine carbon of the azomethine moiety.
Antibacterial activity (in vitro)
The antibacterial activity results of the synthesized 
compounds are presented as % inhibition and minimum 
inhibitory concentration (MIC) values in Table II and 
Table III, respectively. 
Overall, the whole series exhibited moderate 
ant ibacter ia l  ac t iv i ty  wi th  IC 50 comparable  to 
ciprofloxacin, the reference drug. The bacterial strains E. 
coli, P. aeruginosa and S. aureus were inhibited by all the 
synthesized compounds but some were inactive against 
S. typhi and B. subtilis. Half of the series was moderately 
active against all the bacterial strains. Against S. typhi, 
compounds 8g, 8k and 8l were inactive at all dilutions 
and the rest were moderate inhibitors. All compounds 
showed moderate activity against E. coli, where 8g and 
8m were the most effective against this strain bearing 
an O-substituted group at the 4th position of the phenyl 
ring of the benzylidene moiety, p-hydroxyphenyl and 
p-methoxyphenyl, respectively. P. aeruginosa was 
moderately inhibited by all compounds. Although five 
compounds were inactive against B. subtilis, the others 
displayed substantial activity, except 8g. Moderate to 
high inhibitory effect was exerted by all synthesized 
compounds against S. aureus, but 8m was the best. 
The un-substituted benzylidene-bearing molecule, 8a, 
was moderately effective against all strains, but the 
substituted ones exhibited notable variation in their 
antibacterial activity. Among the o- and m-substituted 
ones, molecules bearing methyl/nitro-substituted 
benzylidene moieties (8b, 8h, 8c and 8i) were better 
than those bearing hydroxyl-substituted benzylidene 
moieties (8e and 8f). The molecules bearing p-substituted 
benzylidene moieties showed considerable variation in 
their activity. Compound 8m demonstrated a prominent 
activity against all strains except B. subtilis and most 
probably because of the para methoxy substitutent on 
benzylidene. The low MIC values (µg/mL) shown by 
8m were 9.48 ± 0.00 (S. typhi), 7.37 ± 0.23 (E. coli), 
13.69 ± 1.66 (P. aeruginosa) and 10.88±1.21 (S. aureus), 
compared to MIC of ciprofloxacin, 7.83 ± 0.78, 8.01 ± 
0.12, 7.98 ± 0.89 and 7.00 ± 0.54 respectively. E. coli 
was best inhibited by 8g, also bearing a para hydroxy 
benzylidene, with MIC of 10.78 ± 1.21 µg/mL relative 
to 8.01 ± 0.12 µg/mL. After 8m, the molecule 8j bearing 
p-nitrobenzylidene also exhibited notable activity against 
all strains. Overall, the nitro-substituted benzylidenes 
exerted greater inhibitory effect against all bacterial 
strains relative to the other substituted benzylidenes. The 
TABLE I - Different aryl groups
Comp -R Comp -R Comp -R
8a Phenyl 8f 3-Hydroxyphenyl 8k 4-Dimethylaminophenyl
8b 2-Methylphenyl 8g 4-Hydroxyphenyl 8l 4-Diethylaminophenyl
8c 3-Methylphenyl 8h 2-Nitrophenyl 8m 4-Methoxyphenyl
8d 4-Methylphenyl 8i 3-Nitrophenyl
8e 2-Hydroxyphenyl 8j 4-Nitrophenyl
Synthesis, spectral analysis and pharmacological study of N’-substituted-2-(5-((2,4-dimethylphenoxy)methyl)-1,3,4-oxadiazol-2-ylthio)acetohydrazides 479
hydroxy-substituted benzylidenes were the least active. 
Compounds 8k and 8l showed no activity at all or weakly 
moderate activity.
Enzyme inhibition activity (in vitro)
The results of screening the compounds against 
lipoxygenase activity are given as % inhibition and 
concentration for 50% inhibition (IC50) values in Table 
IV. 
More than half of the synthesized molecules were 
inactive at all dilutions, and only five compounds, 8b, 8c, 
8f, 8h and 8i, showed inhibitory potential varying from 
high to moderate. The lower activity of these molecules 
migh have been attributed to the large molecular size, 
resulting in hindrance to binding with the active site of 
the enzyme. But unexpectedly, molecule, 8i, bearing a 
3-nitrobenzylidene moiety, exerted the highest inhibitory 
effect with IC50 value of 5.21 ± 0.011 µM with respect to 
that of baicalein, 22.4 ± 1.3 µM, the reference standard. 
This better inhibitory effect could be ascribed to some 
additional interaction modes shown by this molecule with 
the amino acid residues at the active site of the enzyme. 
Overall, the results demonstrated that the molecules 
bearing p-substituted benzylidenes were inactive at all 
dilutions. The ortho and meta substituted benzylidenes 
were more effective. The nitro-substituted benzylidenes 
(ortho and meta) were the most active ones among all 
molecules. 
FIGURE 2 - Proposed mass fragmentation pattern of N’-benzylidene-2-(5-((2,4-dimethylphenoxy)methyl)-1,3,4-oxadiazol-2-
ylthio)acetohydrazide (8a).
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CONCLUSION
A series of molecules bearing 1,3,4-oxadiazole and 
azomethine moieties were synthesized with good yields. 
The structures were corroborated using spectral data, 
and these molecules were screened for their antibacterial 
and lipoxygenase inhibitory potentials. High to moderate 
antibacterial activity was demonstrated against certain 
strains of Gram-positive and Gram-negative bacteria. 
These molecules were found to be weak enzyme 
inhibitors except 8i, which showed remarkable inhibition 
of lipoxygenase, as evidenced by its low IC50 value. The 
molecule 8m showed high antibacterial activity might be 
due to p-methoxybenzylidene moiety. This study could be 
TABLE II - The % inhibition of antimicrobial activity of the synthesized compounds
Compound
% Inhibition
Gram negative bacteria Gram positive bacteria
S. typhi E. coli P. aeruginosa B. subtilis S. aureus
8a 78.75±0.75 76.80±0.68 77.55±0.25 72.50±1.21 77.33±1.11
8b 76.25±1.22 67.05±1.37 80.25±1.59 79.29±0.57 70.61±1.43
8c 66.75±0.72 63.90±1.23 59.90±0.58 63.00±1.60 69.83±0.84
8d 68.85±1.22 56.45±1.73 61.10±0.20 60.71±1.30 67.11±0.53
8e 58.85±0.28 61.50±2.17 52.20±0.30 43.21±1.31 71.33±1.00
8f 57.25±0.85 65.30±1.38 52.30±0.59 43.57±1.25 75.28±1.37
8g 47.95±0.72 73.45±1.27 77.50±1.30 66.36±1.67 75.00±0.63
8h 75.90±1.67 76.95±1.14 78.45±0.48 73.43±0.50 77.11±0.61
8i 75.56±1.37 75.05±1.56 71.38±1.87 72.15±1.78 76.89±1.03
8j 75.30±1.89 75.85±1.55 54.65±0.80 70.43±1.42 79.50±0.28
8k 46.75±1.57 60.95±0.78 55.95±0.20 45.72±1.05 71.56±1.58
8l 47.80±1.62 66.55±1.03 54.06±1.35 41.71±0.65 75.06±1.09
8m 80.65±0.94 84.45±0.48 82.35±0.60 81.21±0.90 83.28±1.02
Ciprofloxacin 91.54±0.39 90.98±0.83 91.04±0.65 91.93±0.78 92.20±0.49
TABLE III - The MIC values of antimicrobial activity of the synthesized compounds
Compound
MIC ( µg/ mL)
Gram negative bacteria Gram positive bacteria
S. typhi E. coli P. aeruginosa B. subtilis S. aureus
8a 12.62±0.11 13.32±0.68 12.83±1.11 10.20±0.05 12.85±0.51
8b 13.26±0.90 15.01±0.10 14.43±0.78 10.01±0.55 13.59±1.03
8c 14.53±1.21 16.19±1.30 16.63±1.44 10.51±0.82 13.78±0.19
8d 14.66±0.44 17.34±0.80 16.68±0.11 11.37±0.40 14.69±1.05
8e 17.02±1.22 16.04±0.45 19.13±1.00 - 14.05±0.62
8f 17.42±0.22 16.33±0.60 18.26±0.67 - 13.43±0.54
8g - 10.78±1.21 13.02±0.45 16.44±1.65 13.87±2.34
8h 13.30±1.33 14.33±0.80 12.88±1.33 10.87±0.09 12.70±1.68
8i 13.25±1.67 14.42±0.46 13.18±1.29 10.54±1.54 12.98±2.08
8j 13.22±0.48 14.57±0.07 14.42±0.76 10.08±0.91 12.55±0.05
8k - 15.49±0.70 17.87±1.67 - 14.13±0.92
8l - 15.98±1.10 18.42±0.88 - 13.21±0.98
8m 9.48±0.00 7.37±0.23 13.69±1.66 - 10.88±1.21
Ciprofloxacin 7.83±0.78 8.01±0.12 7.98±0.89 7.22±0.67 7.00±0.54
NOTE: Minimum inhibitory concentration (MIC) was measured with suitable dilutions (5-30 µg/well) and results were calculated 
using EZ-Fit software (Perrella Scientific Inc. Amherst, USA).
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extended to synthesize more derivatives with variation in 
substituted benzylidenes for better results to advance our 
drug discovery programs. 
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